674 related articles for article (PubMed ID: 9951430)
1. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients.
Robatel C; Decosterd LA; Biollaz J; Eckert P; Schaller MD; Buclin T
J Clin Pharmacol; 2003 Dec; 43(12):1329-40. PubMed ID: 14615469
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration.
Fuhrmann V; Schenk P; Jaeger W; Ahmed S; Thalhammer F
J Antimicrob Chemother; 2004 Oct; 54(4):780-4. PubMed ID: 15347636
[TBL] [Abstract][Full Text] [Related]
4. Effect of filtration volume of continuous venovenous hemofiltration in the treatment of patients with acute renal failure in intensive care units.
Brause M; Neumann A; Schumacher T; Grabensee B; Heering P
Crit Care Med; 2003 Mar; 31(3):841-6. PubMed ID: 12626994
[TBL] [Abstract][Full Text] [Related]
5. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.
Isla A; Maynar J; Sánchez-Izquierdo JA; Gascón AR; Arzuaga A; Corral E; Pedraz JL
J Clin Pharmacol; 2005 Nov; 45(11):1294-304. PubMed ID: 16239363
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
Ververs TF; van Dijk A; Vinks SA; Blankestijn PJ; Savelkoul JF; Meulenbelt J; Boereboom FT
Crit Care Med; 2000 Oct; 28(10):3412-6. PubMed ID: 11057794
[TBL] [Abstract][Full Text] [Related]
7. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration.
Joos B; Schmidli M; Keusch G
Nephrol Dial Transplant; 1996 Aug; 11(8):1582-5. PubMed ID: 8856215
[TBL] [Abstract][Full Text] [Related]
10. Principles of antibacterial dosing in continuous renal replacement therapy.
Choi G; Gomersall CD; Tian Q; Joynt GM; Freebairn R; Lipman J
Crit Care Med; 2009 Jul; 37(7):2268-82. PubMed ID: 19487930
[TBL] [Abstract][Full Text] [Related]
11. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Roberts DM; Roberts JA; Roberts MS; Liu X; Nair P; Cole L; Lipman J; Bellomo R;
Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133
[TBL] [Abstract][Full Text] [Related]
12. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
13. Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial.
van der Voort PH; Boerma EC; Koopmans M; Zandberg M; de Ruiter J; Gerritsen RT; Egbers PH; Kingma WP; Kuiper MA
Crit Care Med; 2009 Feb; 37(2):533-8. PubMed ID: 19114909
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration.
Fuhrmann V; Schenk P; Jaeger W; Miksits M; Kneidinger N; Warszawska J; Holzinger U; Kitzberger R; Thalhammer F
J Antimicrob Chemother; 2007 Nov; 60(5):1085-90. PubMed ID: 17855725
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study.
Hayakawa M; Ito Y; Fujita I; Iseki K; Gando S
ASAIO J; 2006; 52(4):398-403. PubMed ID: 16883119
[TBL] [Abstract][Full Text] [Related]
16. Clearance of linezolid via continuous venovenous hemodiafiltration.
Mauro LS; Peloquin CA; Schmude K; Assaly R; Malhotra D
Am J Kidney Dis; 2006 Jun; 47(6):e83-6. PubMed ID: 16731287
[TBL] [Abstract][Full Text] [Related]
17. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.
Thalhammer F; Schenk P; Burgmann H; El Menyawi I; Hollenstein UM; Rosenkranz AR; Sunder-Plassmann G; Breyer S; Ratheiser K
Antimicrob Agents Chemother; 1998 Sep; 42(9):2417-20. PubMed ID: 9736573
[TBL] [Abstract][Full Text] [Related]
18. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients.
Keller E; Fecht H; Böhler J; Schollmeyer P
Nephrol Dial Transplant; 1989; 4(7):640-5. PubMed ID: 2510062
[TBL] [Abstract][Full Text] [Related]
19. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration.
Meyer B; Kornek GV; Nikfardjam M; Karth GD; Heinz G; Locker GJ; Jaeger W; Thalhammer F
J Antimicrob Chemother; 2005 Jul; 56(1):172-9. PubMed ID: 15905303
[TBL] [Abstract][Full Text] [Related]
20. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration.
Krueger WA; Neeser G; Schuster H; Schroeder TH; Hoffmann E; Heininger A; Dieterich HJ; Forst H; Unertl KE
Chemotherapy; 2003 Dec; 49(6):280-6. PubMed ID: 14671427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
